advertisement

---

Bourne R 16

Showing records 1 to 16 | Display all abstracts from Bourne R

98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Ghanchi F
Eye 2022; 36: 1154-1167

---

99265 The economics of vision impairment and its leading causes: A systematic review
Marques AP
EClinicalMedicine 2022; 46: 101354

---

98454 Testing the eligibility of glaucoma patients for potential gene therapy among a clinic population
Gruzei C; Zhang J
International Ophthalmology 2022; 42: 785-797

---

99265 The economics of vision impairment and its leading causes: A systematic review
Ramke J
EClinicalMedicine 2022; 46: 101354

---

98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Bourne R
Eye 2022; 36: 1154-1167

---

98454 Testing the eligibility of glaucoma patients for potential gene therapy among a clinic population
Bourne R
International Ophthalmology 2022; 42: 785-797

---

98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Downes SM
Eye 2022; 36: 1154-1167

---

99265 The economics of vision impairment and its leading causes: A systematic review
Cairns J; Butt T
EClinicalMedicine 2022; 46: 101354

---

98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Gale R
Eye 2022; 36: 1154-1167

---

99265 The economics of vision impairment and its leading causes: A systematic review
Zhang JH
EClinicalMedicine 2022; 46: 101354

---

98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Rennie C
Eye 2022; 36: 1154-1167

---

99265 The economics of vision impairment and its leading causes: A systematic review
Jones I
EClinicalMedicine 2022; 46: 101354

---

98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Tapply I
Eye 2022; 36: 1154-1167

---

99265 The economics of vision impairment and its leading causes: A systematic review
Jovic M
EClinicalMedicine 2022; 46: 101354

---

98429 An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
Sivaprasad S
Eye 2022; 36: 1154-1167

---

99265 The economics of vision impairment and its leading causes: A systematic review
Nandakumar A; Faal H; Taylor H; Bastawrous A; Braithwaite T; Resnikoff S; Khaw PT; Bourne R; Gordon I; Frick K; Burton MJ
EClinicalMedicine 2022; 46: 101354

---